# EDGAR Filing Document

**Accession Number:** 0001636651
**File Stem:** 0001636651-25-000017
**Filing Date:** 2025-12
**Character Count:** 6835
**Document Hash:** f7d76032a5b1718ac58aee53383a978a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001636651-25-000017.hdr.sgml**: 20251211

**ACCESSION NUMBER**: 0001636651-25-000017

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251211

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20251211

**DATE AS OF CHANGE**: 20251211

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ovid Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001636651
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 465270895
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38085
- **FILM NUMBER:** 251564450

**BUSINESS ADDRESS:**
- **STREET 1:** 441 NINTH AVENUE, 14TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001
- **BUSINESS PHONE:** 212-776-4381

**MAIL ADDRESS:**
- **STREET 1:** 441 NINTH AVENUE, 14TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001

?xml version='1.0' encoding='ASCII'? ovid-20251211

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** December 11, 2025

**OVID THERAPEUTICS INC.**

 **(Exact name of Registrant as Specified in Its Charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38085** | **46-5270895** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| **441 Ninth Avenue, 14th Floor**<br>**New York, New York** | | **10001** |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: 646-661-7661**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | OVID | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

------

**Item 5.07&nbsp;&nbsp;&nbsp;&nbsp;Submission of Matters to a Vote of Security Holders.**

Ovid Therapeutics Inc. (the "***Company***") held a special meeting of stockholders (the "***Special Meeting***") on December 11, 2025. As of October 31, 2025, the record date for the Special Meeting, there were 71,212,353 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), outstanding and entitled to vote on the proposals presented at the Special Meeting, of which 38,044,680 shares, or 53.42%, were present in person or represented by proxy at the meeting, which constituted a quorum. Summarized below are descriptions of the proposals voted on at the Special Meeting and the final results for each of the proposals. The proposals set forth below are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 7, 2025.

***Proposal 1*: *Approval of the Increase in Authorized Shares of Common Stock***

The Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of the Company's Common Stock from 125,000,000 to 315,000,000, by the votes set forth in the table below:

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| 34,225,378 | 1,453,502 | 2,365,800 |

---

***Proposal 2: Approval of the Conversion of Series B Preferred Stock and Exercise of the Series A Warrants and Series B Warrants***

The Company's stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock upon the conversion of the Company's Series B Convertible Preferred Stock, par value $0.001 per share (the "Series B Preferred Stock"), and the exercise of Series A Warrants to purchase shares of Common Stock and/or pre-funded warrants (the "Pre-Funded Warrants") to purchase Common Stock (the "Series A Warrants") and Series B Warrants to purchase shares of Common Stock and/or Pre-Funded Warrants (the "Series B Warrants"), by the votes set forth in the table below:

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| 34,251,878 | 1,327,426 | 2,465,376 |

---

***Proposal 3*: *Approval of the Issuance of Securities to Executive Officer, in Accordance with Nasdaq Listing Rule 5635(c)***

The Company's stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(c), the issuance and sale of Series B Preferred Stock, Series A Warrants and Series B Warrants to Jeremy Levin, the Company's Chief Executive Officer, pursuant to the Securities Purchase Agreement, dated October 2, 2025, by and between the Company and the investors party thereto, by the votes set forth in the table below:

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| 34,335,202 | 1,225,141 | 2,484,337 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: December 11, 2025 |  |  |
|  | **OVID THERAPEUTICS INC.** | **OVID THERAPEUTICS INC.** |
|  | By: | /s/ Jeffrey Rona |
|  |  | Jeffrey Rona |
|  |  | Chief Business and Financial Officer |

---